On the morning of February 13, 2026, Hau Giang Pharmaceutical Joint Stock Company (DHG Pharma) held the Closing Ceremony for 2025 and the Labor Conference 2026. The event provided an opportunity for the company to review its outstanding achievements over the past year, while setting operational directions and fostering motivation for a new year filled with expectations and success.

In 2025, DHG Pharma recorded net revenue of VND 5,267 billion, representing an 8% increase compared to 2024, and successfully achieved 101% of its planned target. This positive result was driven by the company’s strategy of developing key products, expanding its distribution network, optimizing operational efficiency, and reaffirming its strong internal capabilities, brand reputation, and the unity and dedication of more than 2,800 employees nationwide.

In addition, 2025 marked an important milestone as DHG Pharma’s Betalactam Plant officially obtained EU-GMP certification granted by the Austrian Agency for Health and Food Safety (BASG). The plant’s compliance with EU-GMP standards for five dosage forms was officially announced on September 19, 2025. The official ceremony celebrating the Betalactam Plant’s achievement of the EU-GMP international standard was successfully held on December 22, 2025, further strengthening DHG Pharma’s reputation and product quality in both domestic and international markets.

To promptly recognize and reward collectives and individuals with outstanding performance in the 2025 labor and innovation emulation movement, DHG Pharma presented various commendation titles with remarkable results: 63 advanced labor teams, including 41 excellent labor teams; 2,579 individuals recognized as Advanced Workers, including 285 individuals awarded the title of Grassroots-level Emulation Fighter; 11 collectives and 86 individuals receiving Certificates of Merit from the City People’s Committee; 41 collectives and 827 individuals recognized for excellent task completion; and 22 collectives and 1,752 individuals recognized for good task completion.

In 2026, with a proactive spirit of innovation and breakthrough, DHG Pharma will continue to promote innovation initiatives, continuously upgrade production lines, and enhance product quality as well as market competitiveness. At the same time, the company remains committed to inheriting and promoting its “human legacy,” preserving and spreading DHG Pharma’s cultural identity - considered a foundation that builds internal strength, fosters cohesion, and supports sustainable development throughout its journey of expansion.

In the near future, DHG Pharma plans to implement more programs in collaboration with local authorities, the healthcare sector, and related organizations to provide healthcare services for communities in remote and underserved areas. These programs will not only deliver medicines, but also provide medical equipment, professional consultations, and awareness-raising activities, contributing to the development of a healthier and more sustainable community.

At every stage of development, DHG Pharma consistently upholds its core values as guiding principles, viewing its cultural identity as a source of pride one that has been preserved and continuously promoted since the very first days of its establishment.

The CEO of DHG Pharma, Mr. Toshifumi Kojima, presented a report on the Company’s 2025 business performance and outlined the operational direction for 2026.

Ms. Phan Vu Anh Ngoc - Head of the Human Resources Department, presented the emulation results honoring individuals and teams that achieved outstanding performance in 2025

At the Closing Ceremony for 2025 and the Labor Conference 2026, DHG Pharma presented certificates of merit and commendation awards to teams and individuals with outstanding achievements in 2025, in recognition of their valuable contributions and to encourage the spirit of emulation throughout the company.

At the Closing Ceremony for 2025 and the Labor Conference 2026, DHG Pharma presented certificates of merit and commendation awards to teams and individuals with outstanding achievements in 2025, in recognition of their valuable contributions and to encourage the spirit of emulation throughout the company.

At the Closing Ceremony for 2025 and the Labor Conference 2026, DHG Pharma presented certificates of merit and commendation awards to teams and individuals with outstanding achievements in 2025, in recognition of their valuable contributions and to encourage the spirit of emulation throughout the company.

Ms. Nguyen Ngoc Diep - Deputy General Director in charge of Manufacturing, representing DHG Pharma, delivered a speech to express sincere gratitude to the leaders of departments and authorities of Can Tho

At the 2026 Employees’ Conference, Mr. Toshifumi Kojima shared meaningful messages and outlined the development direction for the new year. He encouraged all staff to unite, strive for excellence, and achieve even greater successes together in 2026.

Mr. Vo Thanh Hung - Chairman of the DHG Pharma Grassroots Trade Union, reported the results of the Employees’ Conference at the team level and presented the amendments to the Collective Labor Agreement.

Mr. Toshifumi Kojima - the CEO of DHG Pharma, and Mr. Vo Thanh Hung - Chairman of the DHG Pharma Trade Union, signed the Collective Labor Agreement at the 2026 Employees’ Conference.

The signing of the Collective Labor Agreement at the 2026 Employees’ Conference clearly reflects the spirit of partnership and sustainable development between DHG Pharma and its employees.

The atmosphere inside the 2025 Year-End Review Ceremony and the 2026 Employees’ Conference.

The atmosphere inside the 2025 Year-End Review Ceremony and the 2026 Employees’ Conference.